Correlation Between Merck and Larimar Therapeutics

Can any of the company-specific risk be diversified away by investing in both Merck and Larimar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merck and Larimar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Merck Company and Larimar Therapeutics, you can compare the effects of market volatilities on Merck and Larimar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merck with a short position of Larimar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merck and Larimar Therapeutics.

Diversification Opportunities for Merck and Larimar Therapeutics

0.39

Correlation Coefficient

Merck  Larimar Therapeutics

Weak diversification

The 3 months correlation between Merck and Larimar is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Merck Company and Larimar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Larimar Therapeutics and Merck is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merck Company are associated (or correlated) with Larimar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Larimar Therapeutics has no effect on the direction of Merck i.e., Merck and Larimar Therapeutics go up and down completely randomly.

Pair Corralation between Merck and Larimar Therapeutics

Considering the 90-day investment horizon Merck Company is expected to generate 0.28 times more return on investment than Larimar Therapeutics. However, Merck Company is 3.52 times less risky than Larimar Therapeutics. It trades about -0.12 of its potential returns per unit of risk. Larimar Therapeutics is currently generating about -0.13 per unit of risk. If you would invest  12,386  in Merck Company on October 20, 2024 and sell it today you would lose (2,594) from holding Merck Company or give up 20.94% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	99.21%
Values	Daily Returns

Merck Company  vs.  Larimar Therapeutics

Merck Company

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Merck Company has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Larimar Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Larimar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Merck and Larimar Therapeutics

The main advantage of trading using opposite Merck and Larimar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merck position performs unexpectedly, Larimar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will offset losses from the drop in Larimar Therapeutics' long position.

The idea behind Merck Company and Larimar Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.